We are focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey.
Our Approach
With an obesity-first focus, our pipeline is specifically designed to address critical needs in the current therapeutic landscape.
Our Pipeline
Kailera’s four clinical-stage product candidates leverage multiple GLP-1- based mechanisms of action and routes of administration.
Our Clinical Trials
Learn about Kailera’s ongoing clinical trials for people living with obesity.
Recent Press Releases
July 07, 2026
Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535
June 29, 2026
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
June 05, 2026